If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care
Executive Summary
If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight.
You may also be interested in...
First US OTC Oral Contraceptive, Opill Marks Start Of Perrigo's Women’s Health ‘Mega-Brand’
“We do want to be a mega brand offering solutions across the women's sexual health journey. From the moment she enters into that category all the way through to post menopause, including fertility, we will develop out a mega brand,” says CEO Patrick Lockwood-Taylor.
HRA Proposes OTC Norgestrel Birth Control
HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.
HBW Insight’s Key Takeaways From 2021: #1 Join The Self-Care Movement
The first year of the pandemic saw a move among consumers towards prevention and wellness under the banner of "self-care". In 2021, the "self-care movement" really started to gain momentum as these new healthcare habits endured, and companies responded with more wellness options, in some cases even pivoting towards becoming pure self-care players.